NTLA vs. BMY
Compare and contrast key facts about Intellia Therapeutics, Inc. (NTLA) and Bristol-Myers Squibb Company (BMY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NTLA or BMY.
Correlation
The correlation between NTLA and BMY is 0.22, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
NTLA vs. BMY - Performance Comparison
Key characteristics
NTLA:
-0.96
BMY:
0.64
NTLA:
-1.49
BMY:
1.21
NTLA:
0.83
BMY:
1.15
NTLA:
-0.63
BMY:
0.38
NTLA:
-1.77
BMY:
1.57
NTLA:
33.25%
BMY:
11.56%
NTLA:
61.60%
BMY:
28.50%
NTLA:
-93.20%
BMY:
-70.62%
NTLA:
-93.11%
BMY:
-23.12%
Fundamentals
NTLA:
$1.34B
BMY:
$116.92B
NTLA:
-$5.45
BMY:
-$3.58
NTLA:
-0.10
BMY:
1.92
NTLA:
$43.09M
BMY:
$47.44B
NTLA:
$35.51M
BMY:
$33.40B
NTLA:
-$527.52M
BMY:
$5.06B
Returns By Period
In the year-to-date period, NTLA achieves a -60.05% return, which is significantly lower than BMY's 17.38% return.
NTLA
-60.05%
-7.16%
-49.71%
-59.67%
-4.68%
N/A
BMY
17.38%
-0.95%
40.36%
17.50%
1.50%
2.84%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
NTLA vs. BMY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Intellia Therapeutics, Inc. (NTLA) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
NTLA vs. BMY - Dividend Comparison
NTLA has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 4.19%.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NTLA Intellia Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BMY Bristol-Myers Squibb Company | 4.19% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% | 2.46% | 3.31% |
Drawdowns
NTLA vs. BMY - Drawdown Comparison
The maximum NTLA drawdown since its inception was -93.20%, which is greater than BMY's maximum drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for NTLA and BMY. For additional features, visit the drawdowns tool.
Volatility
NTLA vs. BMY - Volatility Comparison
Intellia Therapeutics, Inc. (NTLA) has a higher volatility of 19.57% compared to Bristol-Myers Squibb Company (BMY) at 6.16%. This indicates that NTLA's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
NTLA vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Intellia Therapeutics, Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities